Safety, efficacy, PK and PD biomarker results of the first-in-human study of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor BAY 1436032 in patients (pts) with mIDH1 advanced solid tumours

Authors
Category Primary study
JournalAnn. Oncol.
Year 2019
This article has no abstract
Epistemonikos ID: 54a84a897747d2621e0be1576b99bb80631f0a99
First added on: May 09, 2021